Latest Advances in Lung Cancer Research

Deep-learning model takes a personalized approach to assessing each patient’s risk of lung cancer based on CT scans.

Lung cancer screening may accelerate the shift of the lung cancer stage from an advanced incurable stage toward an early curable disease, which may improve survival.

67% of small smoke particles in the US are due to human-ignited fires are responsible for degrade air quality, causing respiratory illnesses, and premature death.

Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.

The diagnosis of early-stage lung cancer with low-dose CT screening led to high rates of lung cancer-specific survival two decades later.

Mirati’s adagrasib and Keytruda show promise for KRAS G12C-mutated NSCLC with a 49% tumor shrinkage in trials.

Lung cancer screening saves lives. So why so do many at high risk not get one? Only 5.8% of people eligible for a free, low-dose CT scan actually get screened.

A new phase I/II clinical trial shows that repotrectinib had anti tumor activity in participants with the ROS-1-gene.

GSK’s TIM-3 lung cancer drug is moving into a pivotal trial after hitting the mark in the midphase portion of the study.

After results from a phase 2 trial, the FDA granted fast track designation to sapanisertib for patients with certain non–small cell lung cancer.

Scientists discover how air pollution triggers lung cancer in non-smokers, identifying a pathway where tiny PM2.5 particles “wake up” dormant cancer cells, leading to new prevention and treatment opportunities.

Amgen’s Lumakras cut the risk of disease progression or death by 34% compared with the chemotherapy docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer.